Atsushi Fukui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Atsushi Fukui has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Ayano Funamizu
Department of Obstetrics and Gynecology Hirosaki University Graduate School of Medicine 5 Zaifu-cho 036-8562 Hirosaki Aomori Japan
1 shared publicationHideki Mizunuma
Department of Obstetrics and Gynecology Hirosaki University Graduate School of Medicine 5 Zaifu-cho 036-8562 Hirosaki Aomori Japan
1 shared publicationHitomi Chiba
Department of Obstetrics and Gynecology Hirosaki University Graduate School of Medicine 5 Zaifu-cho 036-8562 Hirosaki Aomori Japan
1 shared publicationKohei Fuchinoue
Department of Obstetrics and Gynecology Hirosaki University Graduate School of Medicine 5 Zaifu-cho 036-8562 Hirosaki Aomori Japan
1 shared publicationMai Kamoi
Department of Obstetrics and Gynecology Hirosaki University Graduate School of Medicine 5 Zaifu-cho 036-8562 Hirosaki Aomori Japan
1 shared publicationMegumi Yokota
Department of Obstetrics and Gynecology Hirosaki University Graduate School of Medicine 5 Zaifu-cho 036-8562 Hirosaki Aomori Japan
1 shared publication
Latest Publications
- Open Access
- 11 April 2015
- Published by Wiley in Reproductive Medicine and Biology
- Vol. 14 (4) , 151-157
NK cell abnormality and its treatment in women with reproductive failures such as recurrent pregnancy loss, implantation failures, preeclampsia, and pelvic endometriosis
The regulation of uterine and peripheral blood natural killer (NK) cells has been associated with problems related to reproductive immunology such as recurrent pregnancy loss (RPL), implantation failure or preeclampsia. NKp46, one of the natural cytotoxicity receptors (NCRs), is a unique marker that functions in NK cell cytotoxicity and cytokine production. Expression of NKp46 on NK cells is lower in women with recurrent pregnancy loss and pregnancy‐induced hypertension. Moreover, expression of NKp46 on peritoneal fluid NK cells is lower in women with pelvic endometriosis. Therefore, evaluation of NKp46 on peripheral blood NK cells may provide a means of screening for reproductive abnormalities. Recently, a new type of NK cell, the NK22 cell, has been reported. This cell may be a regulator not only of the mucosal barrier but also of reproduction. For women with RPL showing abnormal uterine and/or peripheral blood NK cells, both intravenous immunoglobulin treatment and intralipid treatment have been reported. The effects of these treatments are still controversial, and further studies are needed in order to clarify their true impact. The present review examines variations in the expression of NCRs on NK cells, the participation of NK22 cells in reproduction, and the possible use of intravenous immunoglobulin or intralipid treatment for women with recurrent pregnancy loss and NK cell abnormality.
- 11 April 2015
- Published by Wiley in Reproductive Medicine and Biology
- Vol. 14 (4) , 151-157
Open AccessNK cell abnormality and its treatment in women with reproductive failures such as recurrent pregnancy loss, implantation failures, preeclampsia, and pelvic endometriosis
The regulation of uterine and peripheral blood natural killer (NK) cells has been associated with problems related to reproductive immunology such as recurrent pregnancy loss (RPL), implantation failure or preeclampsia. NKp46, one of the natural cytotoxicity receptors (NCRs), is a unique marker that functions in NK cell cytotoxicity and cytokine production. Expression of NKp46 on NK cells is lower in women with recurrent pregnancy loss and pregnancy‐induced hypertension. Moreover, expression of NKp46 on peritoneal fluid NK cells is lower in women with pelvic endometriosis. Therefore, evaluation of NKp46 on peripheral blood NK cells may provide a means of screening for reproductive abnormalities. Recently, a new type of NK cell, the NK22 cell, has been reported. This cell may be a regulator not only of the mucosal barrier but also of reproduction. For women with RPL showing abnormal uterine and/or peripheral blood NK cells, both intravenous immunoglobulin treatment and intralipid treatment have been reported. The effects of these treatments are still controversial, and further studies are needed in order to clarify their true impact. The present review examines variations in the expression of NCRs on NK cells, the participation of NK22 cells in reproduction, and the possible use of intravenous immunoglobulin or intralipid treatment for women with recurrent pregnancy loss and NK cell abnormality.